[Ip-health] Save the Date: Feb 24, 2017 - U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents in United States
claire.cassedy at keionline.org
Fri Jan 27 06:44:04 PST 2017
Feb 24, 2017 - U.S. History, Experiences, and Prospects of Compulsory
Licensing of Medical Patents in United States
On Friday, February 24, 2017, KEI will host a meeting exploring compulsory
licensing in the United States.
Title: History, Experiences, and Prospects of Compulsory Licensing on
Medical Patents in the United States
Date: Friday February 24, 2017
Location: Kaiser Permanente Center for Total Health
700 Second St. NE (near Union Station)
Washington, DC 20002
The event will feature presentations and roundtable discussions on the
1. A review of all U.S. legislation proposed, enacted and/or repealed on
the compulsory licensing of patents from the 19th Century to the present.
2. A discussion of the compulsory licensing of patents under 28 USC
1498(a), the statute that covers use of patents “by or for the United
States without license of the owner.”
3. A discussion of the non-voluntary use of patents in court cases
involving requests for permanent injunctions as a remedy to infringement,
under the standards set out in the by the U.S. Supreme Court in eBay Inc.
v. MercExchange, L.L.C., 547 U.S. 388 (2006) .
4. A discussion of the experience with the Bayh-Dole Act march-in
5. A review of compulsory licensing statutes in 12 industrialized
6. A concluding discussion about the need for new statutory authority to
grant compulsory licenses on patents, with references to (a) US government
negotiations on prices of drugs, (b) the broader need to curb excessive
prices of drugs, (c) the role of compulsory licensing in improving access
to research tools, diagnostic tests and upstream technologies such as
CRISPR Genome Editing, and for follow-on inventions.
We will soon share a list of experts and practitioners.
We believe the topic of compulsory licensing is timely and important as the
government considers a range of options to address concerns over high drug
Many patient and consumer groups want to ensure that in disputes over drug
prices, the patent monopoly is at risk, rather than the patient’s access.
If you are interested in attending, please register at the following link
(Note, the room is limited to 50 persons):
Beverages, lunch (with a vegetarian option), and an afternoon snack will be
For more information, please contact Claire.Cassedy at keionline.org,
More information about the Ip-health